Effect of Pexelizumab in Coronary Artery Bypass Graft Surgery with Extended Aortic Cross-clamp Time.
From: Duke University Medical Center, Durham, North Carolina 27710, USA. smith058@mc.duke.edu
The Annals of thoracic surgery
- Publish Date: Sep 2006
- ISSN: 1552-6259
- Volume: 82
- Issue: 3
- Pages: 781-8; discussion 788-9
- Medium: Internet
- Language: English
- Citation (JAMA): Smith Peter K, Carrier Michel, Chen John C, et al. Effect of Pexelizumab in Coronary Artery Bypass Graft Surgery with Extended Aortic Cross-clamp Time.. Ann. Thorac. Surg. Sep 2006;82:781-8; discussion 788-9
Abstract
BACKGROUND: Prolonged cross-clamp time during cardiac surgery increases the risk of postoperative mortality and myocardial injury. This subanalysis from the pexelizumab for reduction of infarction and mortality in coronary artery bypass grafting surgery (PRIMO-CABG) trial, a phase III double-blind, placebo-controlled study of 3,099 patients undergoing on-pump coronary artery bypass graft surgery with or without valve surgery, assessed the impact of pexelizumab, an investigational C5 complement inhibitor, on postoperative outcomes after prolonged aortic cross-clamp time. METHODS: The composite endpoint of death or myocardial infarction through postoperative day 30 and death alone through days 30, 90, and 180 were examined in subpopulations of patients across different cross-clamp times. RESULTS: After prolonged cross-clamping (> or = 90 minutes), death, or myocardial infarction through day 30 and death through days 30, 90, and 180 were significantly increased in the intent-to-treat population and were even higher in patients with two or more prespecified risk factors, compared with all patients cross-clamped less than 90 minutes. Pexelizumab significantly reduced the incidence of death or myocardial infarction through day 30, and significantly reduced the incidence of mortality through day 180, in patients with two or more risk factors that required prolonged cross-clamp time. Pexelizumab also significantly reduced perioperative myocardial injury in all patients requiring prolonged cross-clamp time. CONCLUSIONS: In this retrospective, subgroup analysis, pexelizumab reduced postoperative morbidity and myocardial injury in patients with multiple risk factors who underwent prolonged cross-clamp time during coronary artery bypass surgery. The clinical benefit of pexelizumab may be related to the effect of complement inhibition in the presence of potential ischemic-reperfusion injury associated with prolonged aortic cross-clamp time.
Mesh Headings (Keywords): Antibodies, Monoclonal, Aorta, Biological Markers, Complement Activation, Complement C5, Constriction, Coronary Artery Bypass, Creatine Kinase, MB Form, Double-Blind Method, Follow-Up Studies, Heart Valve Prosthesis Implantation, Humans, Incidence, Life Tables, Myocardial Infarction, Myocardial Reperfusion Injury, Postoperative Complications, Premedication, Recurrence, Retrospective Studies, Risk Factors, Survival Analysis, Time Factors, Treatment Outcome
Check for Full Text / PubMed Unique Identifier (PMID): 16928483
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.